- Intelligent Bio Solutions (INBS, Financial) will participate in the RISE25 conference, showcasing innovative drug testing technology.
- The Intelligent Fingerprinting Drug Testing Solution provides results in under ten minutes.
- INBS maintains over 450 active accounts globally, highlighting strong demand for its solutions.
Intelligent Bio Solutions Inc. (NASDAQ: INBS), a leader in non-invasive testing solutions, will present its Intelligent Fingerprinting Drug Testing Solution at the RISE25 conference in Kissimmee, Florida, from May 28 to 31, 2025. Partnered with SMARTOX, INBS will demonstrate a drug testing system capable of detecting cannabis, cocaine, methamphetamine, and opiates through fingerprint sweat, delivering results in under ten minutes.
The RISE25 conference is an important event in the U.S., focusing on addiction, mental health, and justice innovation, attracting over 7,000 attendees, including professionals across the justice and health sectors. This provides INBS a platform to connect with key stakeholders, as the company seeks FDA approval for broader U.S. market entry this year.
Currently, the Intelligent Fingerprinting Drug Testing System is approved for forensic use in the U.S., with ambitions for expansion. INBS, holding over 450 active accounts across 24 countries, demonstrates a strong global demand for its technology. The company's participation underscores its commitment to advancing health and safety with reliable, on-site drug testing solutions.
Through its strategic collaboration with SMARTOX, founded in 2012, INBS aims to enhance its U.S. market presence and contribute meaningfully to justice and health sectors by providing dignified and effective drug screening solutions.
